Thrive Pet Healthcare and FidoCure have come together to aid the heartbroken families of dogs diagnosed with cancer. Since 2022, more than 50 veterinarians at Thrive Pet Healthcare have utilized FidoCure's precision medicine platform to treat around 400 cases of canine cancer. FidoCure has provided these patients with next-generation sequencing to guide treatments using its patented precision medicine technology, catering to each patient's cancer drivers and providing targeted chemotherapy tailored to their specific needs.
Venya, a 13 ½-year-old German Shepherd, is one of those patients who has been diagnosed with three different types of cancer – including Splenic Hemangiosarcoma. Her owner, Ben Monaco, chose to pursue genetic-based testing through FidoCure, leading to a targeted treatment plan that helped Venya beat the odds. Venya now continues to live a happy, active life.
Christina Lopes, co-founder and CEO of FidoCure, expressed enthusiasm for the partnership, stating that their collaboration with Thrive Pet Healthcare has been instrumental in expanding access to cutting-edge cancer care for dogs. FidoCure has treated over 5,000 dogs, and with their patented novel approach, hope to leave a lasting impact on human cancer care through their cutting-edge genomic sequencing. Alongside Thrive, they are leading the way together for AI-driven drug development in veterinary oncology and ultimately fight cancer on both sides of the leash.
Thrive Pet Healthcare and FidoCure anticipate further advancements in cancer care for pets and humans, driven by the stories of courageous dogs like Venya and the commitment of dedicated veterinary teams. The One Health Company is the first to bring the latest advances in individualized precision medicine to canine cancer patients with its FidoCure Next Generation DNA Sequencing Test.
